By Angela McDaniels
Seattle, Jan. 10 - GlobeImmune Inc. said it has closed a round of series B preferred stock financing.
GlobeImmune added an additional $4.1 million to the previously announced first close of $34.3 million, bringing the total amount raised to $38.4 million.
The series B financing was led by Lilly Ventures and included HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Medica Venture Partners, Adams Street Partners, Biogen Idec Inc., Genentech Inc., Partners Healthcare and GC&H Investments.
New investors in the series B round included PAC-LINK Bio Venture Capital, China Investment and Development and Yasuda Enterprise Development.
GlobeImmune said it has raised $51 million to date.
The company plans to use the series B funds for to complete a placebo-controlled phase 2 clinical trial of GI-4000 in patients with pancreatic cancer and to complete a placebo-controlled phase 1b clinical trial of GI-5005 in patients with chronic hepatitis C infection.
GlobeImmune is a biopharmaceutical company based in Louisville, Colo., that develops and manufactures targeted molecular immunotherapies for the treatment of cancer and infectious diseases.
| Issuer: | GlobeImmune Inc.
|
| Issue: | Preferred stock
|
| Series: | B
|
| Amount: | $4.1 for second tranche, $38.4 million total
|
| Investors: | Lilly Ventures (lead), PAC-LINK Bio Venture Capital, China Investment and Development , Yasuda Enterprise Development, HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Medica Venture Partners, Adams Street Partners, Biogen Idec Inc., Genentech Inc., Partners Healthcare, GC&H Investments
|
| Announcement date: | Jan. 10
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
